Oncotarget

Research Papers:

Reduced expression of chemerin is associated with poor clinical outcome in acute myeloid leukemia

Jing Zhang, Jiao Zhou, Xi Tang, Ling-Yu Zhou, Ling-Ling Zhai, Minse Evola-Deniz Vanessa, Jing Yi, Yun-Yun Yi, Jiang Lin, Jun Qian and Zhao-Qun Deng _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:92536-92544. https://doi.org/10.18632/oncotarget.21440

Metrics: PDF 1196 views  |   HTML 1744 views  |   ?  


Abstract

Jing Zhang1,2, Jiao Zhou1,2, Xi Tang1,2, Ling-Yu Zhou1,2, Ling-Ling Zhai1,2, Minse Evola-Deniz Vanessa1, Jing Yi1,2, Yun-Yun Yi1,2, Jiang Lin1, Jun Qian2 and Zhao-Qun Deng1

1Department of Laboratory Center, The Affiliated People’s Hospital of Jiangsu University, Zhenjiang, 212002, Jiangsu, People’s Republic of China

2Department of Hematology, The Affiliated People’s Hospital of Jiangsu University, Zhenjiang, 212002, Jiangsu, People’s Republic of China

Correspondence to:

Zhao-Qun Deng, email: [email protected]

Jiang Lin, email: [email protected]

Keywords: chemerin, diagnosis, prognosis, acute myeloid leukemia, biomarker

Received: August 01, 2017     Accepted: August 29, 2017     Published: September 30, 2017

ABSTRACT

Chemerin is dysregulation in numerous solid cancers. However, only little is known about the role of chemerin in acute myeloid leukemia (AML). In this study, we aimed to investigate the expression and clinical significance of recently described chemerin in acute myeloid leukemia (AML). The expression of chemerin in 149 patients with de novo AML and 35 normal controls was quantified by Real-time quantitative PCR (RQ-PCR). Chemerin was down-expressed in AML compared with controls (P=0.042). A receiver operating characteristic (ROC) curve revealed that chemerin expression could differentiate patients with AML from control subjects (AUC=0.611, 95% CI: 0.490-0.732; P=0.042) respectively. The cohort of AML patients was divided into two groups according to the cut-off value of 0.0826 (79% sensitivity and 54% specificity, respectively). In addition, the AML patients with low chemerin expression had significantly shorter overall survival (OS) than those with high chemerin expression (P=0.049). Moreover, multivariate survival analysis confirmed that chemerin was an independent prognostic factor for AML patients. In conclusion, downregulation of chemerin might be a useful diagnostic and prognostic factor for AML patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21440